Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J H W Distler

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Zeitschrift Fur Rheumatologie|November 2, 2018
[New molecular mechanisms in the pathophysiology of rheumatic diseases]J H W Distler
Zeitschrift Fur Rheumatologie|April 26, 2008
[Primary and secondary Raynaud's phenomenon]J H W Distler
Rheumatology (Oxford, England)|September 17, 2008
Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosisJ H W Distler, O Distler
Rheumatology (Oxford, England)|September 17, 2008
Criteria to select molecular targets for anti-fibrotic therapyJ H W Distler, O Distler
Annals of the Rheumatic Diseases|December 10, 2009
Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapiesJ H W Distler, O Distler
Rheumatology (Oxford, England)|November 26, 2008
Imatinib as a novel therapeutic approach for fibrotic disordersJ H W Distler, O Distler
Zeitschrift Fur Rheumatologie|June 14, 2014
[Mechanisms of fibrosis and their translation into clinical aspects]C Beyer, J H W Distler
Rheumatology (Oxford, England)|September 22, 2006
Angiogenesis and vasculogenesis in systemic sclerosisJ H W Distler, S Gay, O Distler
Rheumatology (Oxford, England)|November 6, 2008
Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosisJ H W Distler, A Akhmetshina, G Schett, et al.
Rheumatology (Oxford, England)|September 17, 2008
Mechanisms of vascular damage in SSc--implications for vascular treatment strategiesS Guiducci, O Distler, J H W Distler, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Zeitschrift Fur Rheumatologie|November 2, 2018
[New molecular mechanisms in the pathophysiology of rheumatic diseases]J H W Distler
Zeitschrift Fur Rheumatologie|April 26, 2008
[Primary and secondary Raynaud's phenomenon]J H W Distler
Rheumatology (Oxford, England)|September 17, 2008
Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosisJ H W Distler, O Distler
Rheumatology (Oxford, England)|September 17, 2008
Criteria to select molecular targets for anti-fibrotic therapyJ H W Distler, O Distler
Annals of the Rheumatic Diseases|December 10, 2009
Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapiesJ H W Distler, O Distler
Rheumatology (Oxford, England)|November 26, 2008
Imatinib as a novel therapeutic approach for fibrotic disordersJ H W Distler, O Distler
Zeitschrift Fur Rheumatologie|June 14, 2014
[Mechanisms of fibrosis and their translation into clinical aspects]C Beyer, J H W Distler
Rheumatology (Oxford, England)|September 22, 2006
Angiogenesis and vasculogenesis in systemic sclerosisJ H W Distler, S Gay, O Distler
Rheumatology (Oxford, England)|November 6, 2008
Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosisJ H W Distler, A Akhmetshina, G Schett, et al.
Rheumatology (Oxford, England)|September 17, 2008
Mechanisms of vascular damage in SSc--implications for vascular treatment strategiesS Guiducci, O Distler, J H W Distler, et al.
Pageof 3